In Hyperlipidaemia Prolonged Action for Better Results

COMPOSITION – Rosuvastatin Calcium IP 10 mg + Aspirin IP 75 mg + Clopidogrel bisulphate IP 75 mg




  • Drug class: HMG-CoA reductase inhibitors (statins)

Rosuvastatin Calcium

  • Rosuvastatin calcium is one of the most commonly prescribed HMG-CoA reductase inhibitors.
  • Rosuvastatin reduces high sensitivity C reactive protein (hsCRP) which is a marker of inflammation and an independent cardiovascular risk predictor and other inflammatory markers. 
  • Rosuvastatin inhibits platelet aggregation to leukocytes which inhibits the formation of clots in injured endothelium.
  • Rosuvastatin is less likely to cause metabolic drug-to-drug interactions since it has limited metabolism by CYP isoenzymes.
  • A large retrospective cohort study in America found that rosuvastatin produced the largest reduction in LDL-C, non-HDL-C, and triglycerides when compared with other statins like atorvastatin and pravastatin. 


  • The most widely tested antiplatelet regimen was aspirin. The benefit of low-dose aspirin therapy for the secondary prevention of serious cardiovascular events is clear.
  • Aspirin has long been the therapeutic foundation of the secondary prevention of CVD, to which contemporary drugs such as statins, and other antithrombotics have been added.


  • Clopidogrel is a prodrug, which needs to be metabolized in the liver into active metabolites.
  • Clopidogrel efficiently reduces ADP-induced platelet aggregation (a key phenomenon in atherosclerosis & CVD) and prolongs bleeding time and is a safe and efficacious antiplatelet drug.


Rosuvastatin Calcium IP 10 mg + Aspirin IP 75 mg + Clopidogrel bisulphate IP 75 mg


  1. Acute Coronary Syndrome
  2. Hyperlipidemia 
  3. Myocardial Infarction
  4. Stroke Angina